Buy these funds and ETFs to profit from the biotech merger boom
“There have been a mass of deals in the U.S., while on this side of the Atlantic, a number of attractive little biotech stocks have been approached or agreed to bids in the last couple of months.” — John Stepek Blogger’s note: You probably heard about the $43 billion Roche (RHHBY:OTC) bid [...]


TFN provides an independent and practical perspective on the U.S. and global investment markets.